Noxopharm
Turramurra
About Noxopharm
Noxopharm is an Australian publicly-listed (ASX: NOX) clinical stage drug development company. The clinical stage drug candidate is Veyonda® (previously known as NOX-66). Veyonda® is a first-in-class, dual-acting cytotoxic and immuno-oncology drug candidate designed to enhance the effectiveness and safety of both chemotherapy and radiotherapy. At one level, Veyonda® enhances the cancer-killing effect of standard chemotherapy and radiotherapy, thereby enabling lower doses of these toxic therapies to be used.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 501 – 1,000
- Estimated revenue: $1K – $10K
- Total funding: $35.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2020)
- Ticker: asx:NOX
- Website: noxopharm.comsitecontent
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/noxopharm-2235670 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.